目的 探讨卡瑞利珠单抗联合化疗方案治疗晚期胃癌的临床疗效。方法 选择2020年1月—2021年1月重庆市开州区人民医院收治的80例晚期胃癌患者，根据治疗方法将患者分为对照组和观察组，每组各40例。对照组第1天静脉滴注多西他赛注射液，75 mg/m²；第2天静脉滴注盐酸伊立替康注射液，75 mg/m²；第3～16天分2次口服替吉奥胶囊80 mg/m²，连续诱导化疗3个周期。观察组在对照组基础上静脉注射注射用卡瑞利珠单抗，200 mg，21 d为1个周期，连续免疫治疗3个周期。比较两组疗效及安全性，以及治疗前后血清肿瘤标志物和生活质量差异。结果 治疗后，观察组总有效率达52.50%，显著高于对照组的30.00%（P<0.05）。两组治疗后健康状况调查简表（SF-36）各项评分和总分均较治疗前增加（P<0.05），且观察组治疗后SF-36各项评分和总分均显著高于对照组（P<0.05）。两组治疗后血清癌胚抗原（CEA）、糖类抗原199（CA199）水平均较治疗前降低（P<0.05），且观察组治疗后血清CEA、CA199水平明显低于对照组（P<0.05）。治疗期间，观察组Ⅲ度及以上反应性毛细血管增生症发生率高于对照组（P<0.05）。结论 卡瑞利珠单抗联合化疗方案治疗可提高晚期胃癌治疗疗效，不良反应较低，并能降低血清CEA、CA19-9水平，改善患者生活质量。

Objective To investigate the clinical efficacy of carrizumab combined with chemotherapy in treatment of advanced gastric cancer. Methods A total of 80 patients with advanced gastric cancer admitted to People's Hospital of Kaizhou District from January 2020 to January 2021 were selected and divided into control group and observation group according to treatment methods, with 40 patients in each group. Patients in the control group were iv administered with Docetaxel Injection on the first day, 75 mg/m²; Irinotecan Hydrochloride Injection was intravenously injected on the second day, 75 mg/m²; From 3 to 16 days, Tegafur,Gimeracil and Oteracil Potassium Capsules 80 mg/m² was taken orally twice daily, and induction chemotherapy was conducted for 3 consecutive cycles. Patients in the observation group were iv administered with with Carrizumab for injection, 200 mg, 21 d as a cycle, and immunotherapy lasted for 3 cycles. The therapeutic effect, serum tumor markers, and quality of life before and after treatment were compared between two groups. Results After treatment, the total effective rate of the observation group was 52.50%, which was significantly higher than 30.00% of the control group (P < 0.05). After treatment, the scores and total scores of SF-36 in two groups were increased compared with before treatment (P < 0.05), and the scores and total scores of SF-36 in the observation group were significantly higher than those in the control group (P < 0.05). After treatment, serum levels of CEA and CA199 in two groups were decreased compared with before treatment (P < 0.05), and the CEA and CA199 levels in observation group were significantly lower than those in control group after treatment (P < 0.05). During the treatment, the incidence of Ⅲ degree or above reactive capillary hyperplasia in the observation group was higher than that in the control group (P < 0.05). Conclusion Carrelizumab combined with chemotherapy can improve the curative effect of advanced gastric cancer with low adverse reactions, reduce serum CEA and CA19-9 levels, and improve the quality of life of patients.